Clinical Trial Update: Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating perioperative surufatinib plus sintilimab with chemotherapy for gastric cancer and gastroesophageal junction cancer; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Sintilimab (sintilimab)
• Surufatinib (Surufatinib)

Snippet

Sponsor: Fudan University | Conditions: Gastric Cancer, Gastro Esophageal Junction Cancer | Phase 2 | Status: NOT_YET_RECRUITING